Second death triggers hold on Astellas' $3B gene therapy biotech's lead program, raising fresh concerns about AAV
Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.
The incidents are derailing plans to file for a near-term approval, which had been expected right about now.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.